For the prevention of meningococcal group B disease (also known as meningitis B)

Because they share

Talk to your healthcare provider about vaccinating with TRUMENBA

INDICATION
- Trumenba is a vaccine indicated for individuals 10 through 25 years of age for active immunization to prevent invasive disease caused by Neisseria meningitidis group B
- Trumenba is approved based upon demonstrated immune response against four group B strains representative of prevalent strains in the US. The effectiveness of Trumenba against diverse group B strains has not been confirmed

IMPORTANT SAFETY INFORMATION
- Trumenba should not be given to anyone with a history of a severe allergic reaction after a previous dose of Trumenba
- Individuals with weakened immune systems may have a reduced immune response

TRUMENBA is proven to help protect 10 through 25 year olds against uncommon, but potentially deadly, meningitis B

Please see full Important Safety Information on page 4 and click here for full Prescribing Information.
There are 5 primary types of the bacteria that cause meningococcal disease: A, C, Y, W, and B⁴.

There have been vaccines approved to protect against A, C, Y, and W. Until 2014 in the US, there were no vaccines to protect against B⁴.

Though not common, when it occurs, meningitis B, like other forms of meningococcal disease, may potentially lead to:

- Death within 24 hours
- Brain damage
- Hearing loss
- Loss of limbs
- Scarring

Meningitis B, a form of invasive meningococcal disease, is a bacterial infection that attacks the brain and spinal cord³.

Info to know and share

Did you know?
The bacteria that cause meningitis B spread through typical adolescent behavior, like kissing; sharing drinks, utensils, and cosmetics; and living in close quarters.³

Your child may be sharing more than they think

In the US, meningitis B is responsible for approximately 30% of invasive meningococcal disease cases (11 through 24 years of age)⁴.

On average, 1 in 10 adolescents and young adults who develop meningitis B will die from it⁶.

Early symptoms of meningitis B may seem like the flu; you and your child may not realize it’s something serious until it’s too late³.

INDICATION
- Trumenba is a vaccine indicated for individuals 10 through 25 years of age for active immunization to prevent invasive disease caused by Neisseria meningitidis group B.
- Trumenba is approved based upon demonstrated immune response against four group B strains representative of prevalent strains in the US. The effectiveness of Trumenba against diverse group B strains has not been confirmed.

IMPORTANT SAFETY INFORMATION
- Individuals with weakened immune systems may have a reduced immune response.
- The most common adverse reactions were pain at the injection site, fatigue, headache, muscle pain, and chills.

Please see full Important Safety Information on page 4 and click here for full Prescribing Information.
Help protect your children, 10 through 25 years of age, against meningitis B, with TRUMENBA

Approved by the FDA for the prevention of meningitis B

- TRUMENBA is a meningitis B vaccine clinically studied in the United States¹
- Patients in TRUMENBA clinical trials were adolescents and young adults²

How TRUMENBA works

- Only TRUMENBA targets both subfamilies of factor H binding protein (fHBP), a protein found in over 97% of disease-causing meningitis B bacteria¹,²
- This means TRUMENBA provides protection against meningitis B strains¹

Talk to your healthcare provider about vaccinating your child against meningitis B, with TRUMENBA

Use the following table to track your child’s dosing schedule to ensure that he or she gets all 3 recommended doses

<table>
<thead>
<tr>
<th>Dose</th>
<th>(Days after previous dose)</th>
<th>Get it</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose 1</td>
<td>(now)</td>
<td></td>
</tr>
<tr>
<td>Dose 2</td>
<td>(2 months after dose 1)</td>
<td></td>
</tr>
<tr>
<td>Dose 3</td>
<td>(6 months after dose 1)</td>
<td></td>
</tr>
</tbody>
</table>

INDICATION

- Trumenba is a vaccine indicated for individuals 10 through 25 years of age for active immunization to prevent invasive disease caused by Neisseria meningitidis group B
- Trumenba is approved based upon demonstrated immune response against four group B strains representative of prevalent strains in the US. The effectiveness of Trumenba against diverse group B strains has not been confirmed

IMPORTANT SAFETY INFORMATION

- Data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series

Please see full Important Safety Information on page 4 and click here for full Prescribing Information.
The most commonly reported adverse reactions were pain at the injection site, fatigue, headache, muscle pain, and chills. The safety data demonstrated that TRUMENBA was generally well tolerated. Important safety info about TRUMENBA

INDICATION
- Trumenba is a vaccine indicated for individuals 10 through 25 years of age for active immunization to prevent invasive disease caused by Neisseria meningitidis group B
- Trumenba is approved based upon demonstrated immune response against four group B strains representative of prevalent strains in the US. The effectiveness of Trumenba against diverse group B strains has not been confirmed

IMPORTANT SAFETY INFORMATION
- Trumenba should not be given to anyone with a history of a severe allergic reaction after a previous dose of Trumenba
- Individuals with weakened immune systems may have a reduced immune response
- The most common adverse reactions were pain at the injection site, fatigue, headache, muscle pain, and chills
- Data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
- Tell your healthcare provider if you are pregnant, or plan to become pregnant
- Ask your healthcare provider about the risks and benefits of Trumenba. Only a healthcare provider can decide if Trumenba is right for you or your child

Click here for full Prescribing Information.
TRUMENBA helps protect 10 through 25 year olds against meningitis B¹

INDICATION
- Trumenba is a vaccine indicated for individuals 10 through 25 years of age for active immunization to prevent invasive disease caused by Neisseria meningitidis group B
- Trumenba is approved based upon demonstrated immune response against four group B strains representative of prevalent strains in the US. The effectiveness of Trumenba against diverse group B strains has not been confirmed

IMPORTANT SAFETY INFORMATION
- Trumenba should not be given to anyone with a history of a severe allergic reaction after a previous dose of Trumenba
- Individuals with weakened immune systems may have a reduced immune response

Get serious about protection—talk to your healthcare provider about vaccinating your child with TRUMENBA

For more information, visit BecauseTheyShare.com

References: